ELLICOTT CITY, Md., Feb. 12, 2018 /PRNewswire/ — The Society for Clinical Research Sites (SCRS) announced today that Boehringer Ingelheim has joined the organization as a Global Impact Partner (GIP). SCRS' GIP Program provides a unique opportunity for sponsors, CROs and vendors to engage with SCRS and its members in an impactful manner. Becoming a GIP demonstrates the company's commitment to clinical research sites and their desire to develop a deeper understanding of the needs of sites, and contribute to the development and implementation of solutions. 

"We look forward to working with SCRS to identify innovative approaches to working with sites as partners and to collaborate with other industry leaders to advance the clinical trial process," said Theresa Devins, senior associate director for Boehringer Ingelheim. "With SCRS' global reach, there is great potential in developing synergies across our organizations internationally and domestically. We are excited to join SCRS as a Global Impact Partner!"

"Boehringer Ingelheim's commitment to ongoing collaboration with sites is refreshing and appreciated by SCRS and all sites," said SCRS president Christine Pierre. "We are excited Boehringer Ingelheim is showing their support of the sites through collaboration with SCRS as a GIP. As we like to remind everyone, site success means your success and SCRS is pleased to be the conduit to make this happen!"

About Boehringer Ingelheim   
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.

SOURCE Society for Clinical Research Sites